Kadcyla Archives -

Market Access/ News/ News/ News/ Oncology

AZ, Daiichi challenge Roche with EU okay for earlier use of Enhertu

Phil Taylor AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, EU, her2, Kadcyla, regulatory approval, Roche, Seagen, Tukysa 0 Comment

AstraZeneca and Daiichi Sankyo have claimed approval in the EU for Enhertu as a second-line therapy for HER2-positive

AZ, Daiichi challenge Roche with EU okay for earlier use of Enhertu

https://pharmaphorum.com/news/az-daiichi-challenge-roche-with-eu-okay-for-earlier-use-of-enhertu/

Market Access/ News/ News/ News/ Oncology

Byondis cues up US, EU decisions on breast cancer ADC in 2023

Phil Taylor AstraZeneca, breast cancer, Byondis, Daiichi Sankyo, Enhertu, her2, Kadcyla, Oncology, Roche 0 Comment

Byondis has filed its HER2-targeting antibody-drug conjugate (ADC) trastuzumab duocarmazine in the US and Europe, setting up possible

Byondis cues up US, EU decisions on breast cancer ADC in 2023

https://pharmaphorum.com/news/byondis-cues-up-us-eu-decisions-on-breast-cancer-adc-in-2023/

News/ News/ Oncology

Enhertu nabs speedy FDA review for earlier use in breast cancer

Phil Taylor AstraZeneca, breakthrough Therapy, breast cancer, Daiichi Sankyo, Enhertu, fda, Kadcyla, Oncology, Roche 0 Comment

Hard on the heels of impressive new data for Enhertu as a second-line therapy for breast cancer, AstraZeneca

Enhertu nabs speedy FDA review for earlier use in breast cancer

https://pharmaphorum.com/news/enhertu-nabs-speedy-fda-review-for-earlier-use-in-breast-cancer/

News/ News/ Oncology

ESMO21: Enhertu brings it’s A game to second-line breast cancer

Phil Taylor AstraZeneca, Daiichi Sankyo, Enhertu, ESMO, HER2-positive breast cancer, Kadcyla, Roche 0 Comment

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC)

ESMO21: Enhertu brings it’s A game to second-line breast cancer

https://pharmaphorum.com/news/esmo21-enhertu-brings-its-a-game-to-second-line-breast-cancer/

News/ News/ Oncology

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

Phil Taylor antibody-drug conjugate, AstraZeneca, breast cancer, disitamab vedotin, Enhertu, her2, Kadcyla, Oncology, RemeGen, Roche, Seagen 0 Comment

Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

https://pharmaphorum.com/news/her2-heats-up-as-seagen-licenses-remegen-adc-for-2-6bn/

News/ News/ Oncology

Ambrx tries another IPO as it chases down HER2 rivals

Phil Taylor Ambrx Biopharma, antibody-drug conjugate, AstraZeneca, Enhertu, financing, her2, IPO, Kadcyla, Roche 0 Comment

California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock

Ambrx tries another IPO as it chases down HER2 rivals

https://pharmaphorum.com/news/ambrx-tries-another-ipo-as-it-chases-down-her2-rivals/

Market Access/ News/ News/ Oncology

NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use

Richard Staines breast cancer, cancer, cost-effectiveness, Kadcyla, market access, NICE, Roche 0 Comment

NICE has published final draft guidance recommending regular NHS funding for Roche’s Kadcyla (trastuzumab emtansine) in its newer use, for certain people

NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use

https://pharmaphorum.com/market-access-2/nice-backs-nhs-funding-for-roches-kadcyla-in-early-breast-cancer-use/

Oncology/ Partner content/ Partner Content/ Press releases/ R&D

Exclusive Pfizer Speaker Interview Released

Pavan Solanki adc, her2, immune-oncology, Kadcyla, PK-PD 0 Comment

Exclusive Pfizer Speaker Interview Released

https://pharmaphorum.com/partner-content-oncology/exclusive-pfizer-speaker-interview-released/

Articles/ Digital and Social Media/ Pharma Market Access/ UK & Europe/ Views and analysis

What HCPs say about Roche’s breast cancer drug

Marco Ricci breast cancer, cancer, Kadcyla, patient centricity, patient groups, patients, Roche, social listening, What HCPs Think, WhatHCPsThink 0 Comment

The online conversations about breast cancer drug Kadcyla before it was approved by NICE.

What HCPs say about Roche’s breast cancer drug

https://pharmaphorum.com/views-and-analysis/roche-breast-cancer-drug/

Trending

Kadcyla

Login